A Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancers with DDR2 or Inactivating BRAF Mutations

Full Title
Phase II Trial of Dasatinib in Subjects with Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Dasatinib is a drug approved for the treatment of leukemia. Studies have shown it can also prevent the growth of non-small cell lung cancer cells with mutations in the DDR2 and BRAF genes. These mutations alter how the DDR2 and BRAF proteins work.

This study is assessing the safety and effectiveness of dasatinib in patients with advanced squamous cell carcinoma of the lung and a DDR2 mutation, and in patients with advanced non-small cell lung cancer with an inactivating BRAF mutation. Dasatinib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have squamous cell carcinoma of the lung and a DDR2 mutation or non-small cell lung cancer and an inactivating BRAF mutation.
  • Patients’ tumors must be locally advanced or metastatic and unable to be surgically removed or cured with standard therapies.
  • At least 1 week must have passed since the completion of prior therapy and entry into the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study or to inquire about eligibility, please contact Dr. Paul K. Paik at 646-888-4202.

Lung Cancer
Lung Cancer, Non-Small Cell
Related Diseases